Leronlimab reduced CCL5-induced MDA-MB-231 breast cancer cell invasion with similar efficacy as vicriviroc (Fig. 4a, b) (855 ± 8.7, N = 8 for control vs. 520 ± 9.1 μM distance traveled, N = 9 for leronlimab, P < 0.001). This evidence concerns the gene CCL5 and breast carcinoma.